Clinical Trials Directory

Trials / Completed

CompletedNCT03199118

Use of Platelet Rich Fibrin in Addition to CAF and SCTG for Treatment of Gingival Recession

The Use of Coronally Advanced Flap and Subepithelial Connective Tissue Graft With or Without Platelet Rich Fibrin in the Treatment of Miller Class I or II Gingival Recession: a Randomized Clinical Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
28 (actual)
Sponsor
Cairo University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This research will be conducted in an attempt to achieve complete root coverage with physiologic probing depth and a harmonious view with the adjacent tissues using Platelet rich fibrin in conjunction with Coronally advanced flap and subepithelial connective tissue graft.

Detailed description

The study population will be divided into 2 groups: Group 1: Patients suffering from Miller class I or II gingival recession will be treated with a coronally advanced flap in conjunction with a sub-epithelial connective tissue graft. The patients should be non-smoker, medically free and above 18 years Group 2: Patients suffering from Miller class I or II gingival recession will be treated with a coronally advanced flap in conjunction with a sub-epithelial connective tissue graft and platelet rich fibrin. the patients should meet the same inclusion criteria mentionned above.

Conditions

Interventions

TypeNameDescription
PROCEDURECAF +SCTGthe use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
OTHERplatelet rich fibrinin addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession

Timeline

Start date
2018-01-01
Primary completion
2019-12-31
Completion
2019-12-31
First posted
2017-06-26
Last updated
2021-03-22
Results posted
2021-03-22

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03199118. Inclusion in this directory is not an endorsement.